共 50 条
- [31] Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational StudyBLOOD, 2015, 126 (23)Nicolini, Franck E.Heiblig, MaelMorisset, StephaneCaillot, DenisCoiteux, ValerieCharbonnier, AudeHuguet, FrancoiseDubruille, VivianeEtienne, GabrielLenain, PascalGuilhot, FrancoisLegros, LaurenceRousselot, PhilippeAme, ShantiDeFrance, RemyRuby, JeremyMahon, Francois-XavierRea, Delphine
- [32] The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study GroupINTERNAL MEDICINE, 2018, 57 (01) : 17 - 23Iriyama, NoriyoshiOhashi, KazuteruHashino, SatoshiKimura, ShinyaNakaseko, ChiakiTakano, HinaHino, MasayukiUchiyama, MichihiroMorita, SatoshiSakamoto, JunichiSakamaki, HisashiInokuchi, Koiti
- [33] Lower dose of imatinib provides outcomes similar to the standard dose imatinib in Japanese patients with early chronic-phase CML: The interim analyses of JALSG CML202 studyBLOOD, 2007, 110 (11) : 316A - 316AOhnishi, KazunoriNishimura, MikiTakeuchi, JinFujisawa, ShinNagai, TadashiMiyamura, KoichiKimura, YukihikoYagasaki, FumiharuAkiyama, HidekiUsui, NorikoOhtake, Shigeki
- [34] Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)BLOOD, 2017, 130Cortes, Jorge E.Nicolini, Franck EmmanuelHochhaus, Andreasle Coutre, Philipp D.Kim, Dong-WookPinilla-Ibarz, JavierPaquette, RonaldChuah, CharlesApperley, Jane F.Talpaz, MosheDeAngelo, Daniel J.Abruzzese, ElisabettaRea, DelphineMueller, Martin C.Gambacorti-Passerini, CarloCastagnetti, FaustoLustgarten, StephanieNeumann, FrankClackson, Timothy P.Guilhot, FrancoisDeininger, Michael W.Hughes, Timothy P.Shah, Neil P.Kantarjian, Hagop M.
- [35] CLINICAL-STUDY OF RECURRENCE RATE AND SURVIVAL TIME OF PATIENTS WITH CARCINOMA OF BREAST TREATED BY BIOPSY EXCISION WITHOUT ANY OTHER THERAPYJOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1978, 71 (05) : 339 - 342MONTGOMERY, ACVGREENING, WPLEVENE, AL
- [36] Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based StudyBLOOD, 2016, 128 (22)Jiang, QianHu, JiandaZheng, FangDu, XinMeng, LiWu, DepeiLiu, BingchengLiu, ZhuogangMa, JunHou, MingQian, SixuanZeng, QingshuHu, YuHuang, Xiaojun
- [37] Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE StudyBLOOD, 2015, 126 (23)Cortes, Jorge E.Kim, Dong-WookPinilla-Ibarz, Javierle Coutre, Philipp D.Paquette, RonaldChuah, CharlesNicolini, Franck E.Apperley, Jane F.Khoury, H. JeanTalpaz, MosheDeAngelo, Daniel J.Abruzzese, ElisabettaRea, DelphineBaccarani, MicheleMueller, Martin C.Gambacorti-Passerini, CarloLustgarten, StephanieConlan, MaureenGuilhot, FrancoisDeininger, Mochael W.Hochhaus, AndreasHughes, Timothy P.Kantarjian, Hagop M.Shah, Neil P.
- [38] OBSERVATIONAL STUDY OF HAIR FALL IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH LOW DOSE METHOTREXATE COMPARED TO HEALTHY CONTROLSANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 750 - 751Kumar, SharathLokanath, Dhivya
- [39] Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)BLOOD, 2014, 124 (21)Mauro, MichaelGambacorti-Passerini, CarloGoldberg, Stuart L.Cortes, Jorge E.Khoury, H. JeanMichallet, MauricettePaquette, RonaldSimonsson, BengtTurner, Michelle P.Mohamed, HeshamSubar, MilaynaZyczynski, Teresa
- [40] A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)BLOOD, 2022, 140 : 12618 - 12620Roussel, MurielleMollee, PeterHuart, AntoineSidiqi, HasibHorvath, NoemiKarlin, LionelJacquet, CarolineMorel, PierreLeyronnas, CecileBender, SebastienBridoux, FrankJaccard, ArnaudGibbs, Simon D.